Patterson BJ, Buck PO, Curran D, van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Chintakayala P, Young W, Barkemeyer R, Morris MA. Breaking niche sustainable products into the mainstream: organic milk and free-range eggs. Bus Srateg Environ. 2018 Mar 30. doi: 10.1002/bse.2050
Young CW, Russell SV, Robinson CA, Chintakayala PK. Sustainable retailing - influencing consumer behaviour on food waste. Bus Srateg Environ. 2018 Jan;27(2):1-15. doi: 10.1002/bse.1966
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Reed (Earnshaw) SR, Reed JH, Stuhldreher TJ. Transaction costs, taxes, and portfolio revision. J Contemp Bus Issue. 1997;5:40-8.